A dose response study comparing Duovent vs salbutamol

Area of Science:

• Pharmacology
• Respiratory Medicine

Background:

• Asthma and chronic bronchitis are significant respiratory conditions requiring effective bronchodilator therapy.
• Fenoterol/ipratropium (Duovent) and salbutamol are commonly used bronchodilators.
• Understanding dose-response relationships is crucial for optimizing treatment.

Purpose of the Study:

• To compare the dose-response profiles of Duovent and salbutamol.
• To evaluate the bronchodilator efficacy and duration of action of both medications in patients with asthma and chronic bronchitis.

Main Methods:

• A double-blind, controlled study involving 30 patients (21 asthma, 9 chronic bronchitis).
• Patients received 1, 2, 4, or 6 puffs of Duovent or salbutamol on separate days.
• Forced expiratory volume in 1 second (FEV1), pulse, and tremor were measured post-inhalation.

Main Results:

• Both Duovent and salbutamol provided effective bronchodilation at all tested doses.
• Duovent showed significantly greater bronchodilation than salbutamol at 2, 4, and 6 puffs in both patient groups.
• Two puffs of Duovent were more effective than any dose of salbutamol; salbutamol's maximal effect was seen with one puff.
• Duovent's FEV1 improvement increased with doses up to 4 puffs, with no further benefit at 6 puffs.
• No significant differences in pulse rate or tremor were observed between the two medications.

Conclusions:

• Duovent offers a greater and more sustained bronchodilator response compared to salbutamol.
• This suggests Duovent may be a more effective treatment option for managing bronchoconstriction in asthma and chronic bronchitis.
• The study highlights the superior dose-dependent efficacy of the fenoterol/ipratropium combination.